ATEC Alphatec Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1350653 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY43.9%
TTM EPS YoY45.2%
Revenue 3-yr CAGR23.1%
Net income 3-yr CAGR—
Margins
Gross margin71.3%
Operating margin-3.6%
Net margin-10.3%
FCF margin0.4%
EBITDA margin4.7%
Returns
ROE-1,888.0%
ROA-11.0%
ROIC (approx.)-5.4%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity—
Current ratio2.36x
Interest coverage-0.65x
Cash quality & payout
Operating cash flow / net income-0.71x
Accruals ratio-18.7%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $221.17M | $213.51M | $192.11M | $212.93M | $196.50M | $185.54M | $169.18M | $176.79M |
| Cost of revenue | $62.93M | $59.41M | $55.63M | $63.44M | $59.20M | $56.44M | $53.18M | $55.20M |
| Gross profit | $158.25M | $154.10M | $136.48M | $149.49M | $137.30M | $129.10M | $116.00M | $121.59M |
| R&D expense | $18.00M | $18.17M | $17.56M | $22.28M | $18.68M | $18.28M | $16.58M | $23.24M |
| SG&A expense | $132.50M | $134.00M | $137.06M | $128.70M | $124.30M | $118.51M | $127.02M | $114.54M |
| Operating income | $3.25M | -$1.91M | -$22.58M | -$8.82M | -$15.93M | -$13.09M | -$44.29M | -$23.82M |
| Interest expense | $10.62M | $10.96M | $11.72M | $12.89M | $12.88M | $12.31M | $7.84M | $7.15M |
| Pretax income | -$7.46M | -$25.62M | -$33.86M | -$21.75M | -$28.50M | -$41.18M | -$51.97M | -$32.89M |
| Income tax | $1.99M | $156,000 | $50,000 | -$18,000 | $74,000 | -$37,000 | -$64,000 | $441,000 |
| Net income | -$5.47M | -$25.78M | -$33.91M | -$21.73M | -$28.58M | -$41.14M | -$51.91M | -$33.33M |
| EBITDA | $19.05M | $13.29M | -$3.45M | $10.28M | -$1.03M | $1.92M | -$24.38M | -$3.81M |
| EPS (basic) | -0.03 | -0.16 | -0.22 | — | -0.19 | -0.27 | -0.35 | — |
| EPS (diluted) | -0.03 | -0.16 | -0.22 | — | -0.19 | -0.27 | -0.35 | — |
| Weighted avg. shares (diluted) | 157.38M | 156.57M | 154.05M | — | 151.40M | 149.91M | 146.73M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $79.94M | $118.66M | $139.91M | $160.81M | $155.74M | $157.06M | $153.24M | $138.84M |
| Receivables | $110.80M | $110.13M | $106.38M | $97.30M | $96.84M | $95.92M | $89.48M | $82.99M |
| Inventory | $206.87M | $194.89M | $186.03M | $169.44M | $166.89M | $169.76M | $170.87M | $175.26M |
| Current assets | $427.17M | $449.01M | $456.17M | $450.88M | $439.78M | $443.33M | $434.89M | $417.40M |
| PP&E, net | $139.70M | $139.24M | $138.04M | $135.32M | $138.23M | $139.73M | $146.64M | $156.39M |
| Goodwill | $73.96M | $74.17M | $74.47M | $75.21M | $75.20M | $75.22M | $72.33M | $70.98M |
| Intangibles | $96.45M | $88.30M | $66.89M | $93.45M | $96.04M | $95.59M | $95.04M | $93.52M |
| Total assets | $796.75M | $791.03M | $799.48M | $791.21M | $787.25M | $790.29M | $785.47M | $775.71M |
| Current liabilities | $180.77M | $237.97M | $240.24M | $219.18M | $220.82M | $154.18M | $157.87M | $153.03M |
| Short-term debt | $5.30M | $65.01M | $65.52M | $64.53M | $64.66M | $1.93M | $2.57M | $1.66M |
| Long-term debt | $541.70M | $510.74M | $507.89M | $501.41M | $495.02M | $551.99M | $545.83M | $574.52M |
| Total debt | $547.00M | $575.75M | $573.41M | $565.94M | $559.68M | $553.92M | $548.40M | $576.18M |
| Total liabilities | $775.44M | $779.49M | $781.22M | $755.18M | $752.14M | $742.92M | $847.81M | $766.28M |
| Shareholders' equity | -$2.30M | -$12.07M | -$5.35M | $12.43M | $11.51M | $23.77M | -$85.94M | -$14.17M |
| Net debt | $467.06M | $457.09M | $433.50M | $405.13M | $403.94M | $396.85M | $395.16M | $437.34M |
| Shares outstanding | 155.22M | 154.49M | 153.79M | 150.26M | 149.35M | 148.84M | 146.91M | 144.13M |
| Cash flow statement | ||||||||
| Operating cash flow | $18.86M | $20.51M | $1.29M | $20.68M | $14.04M | $15.55M | -$5.04M | $10.52M |
| Capital expenditure | $13.29M | $19.93M | $12.09M | $12.96M | $9.23M | $10.32M | $9.93M | $1.98M |
| Free cash flow | $5.57M | $582,000 | -$10.80M | $7.72M | $4.81M | $5.22M | -$14.97M | $8.55M |
| Investing cash flow | -$21.81M | -$22.71M | -$19.89M | -$15.73M | -$13.89M | -$12.17M | -$11.61M | -$3.75M |
| Financing cash flow | -$35.69M | -$19.53M | -$1.77M | $206,000 | -$1.31M | $366,000 | $30.76M | $50.64M |
| Depreciation & amortization | $15.80M | $15.20M | $19.14M | $19.10M | $14.90M | $15.00M | $19.91M | $20.01M |
| Stock-based compensation | $13.95M | $18.15M | $23.66M | $19.40M | $16.38M | $15.62M | $22.32M | $21.53M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.